Novavax, Inc. Q3 2025 Earnings Recap

NVAX Q3 2025 November 6, 2025

Get alerts when NVAX reports next quarter

Novavax demonstrated significant progress in Q3 2025, strengthening its partnership strategies and advancing its diversified R&D pipeline while achieving substantial cash flow, underscoring a shift towards long-term profitability and growth.

Earnings Per Share Beat

$-0.62 vs $-1.08 est.

+42.6% surprise

Revenue Miss

70445000 vs 90258480 est.

-22.0% surprise

Market Reaction

1-Day -1.3%

5-Day -3.25%

30-Day -13.0%

See NVAX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved approximately $1.1 billion in nondilutive cash flow over 8 quarters, bolstered by $800 million from partnerships.
Successfully secured $225 million from Sanofi-related milestones, including key regulatory approvals for Nuvaxovid.
Launched new early-stage R&D initiatives targeting infectious diseases and oncology, emphasizing a diversified pipeline beyond COVID-19.
Initiated cost-saving measures, including consolidating facilities to enhance financial strength, projected to save approximately $230 million.
Positioned to potentially reach non-GAAP profitability by 2028 through a revamped revenue mix driven by partnerships and royalties.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NVAX on AllInvestView.

Next Q1 2026